Compare INUV & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | LPCN |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 13.8M |
| IPO Year | N/A | N/A |
| Metric | INUV | LPCN |
|---|---|---|
| Price | $2.56 | $5.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $14.00 | $7.00 |
| AVG Volume (30 Days) | ★ 109.0K | 66.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,139,861.00 | $4,322,693.00 |
| Revenue This Year | $20.86 | N/A |
| Revenue Next Year | $14.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 25.11 | N/A |
| 52 Week Low | $2.34 | $2.52 |
| 52 Week High | $7.90 | $5.50 |
| Indicator | INUV | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 88.19 |
| Support Level | $2.50 | $4.07 |
| Resistance Level | $2.77 | $3.39 |
| Average True Range (ATR) | 0.17 | 0.33 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 11.65 | 99.09 |
Inuvo Inc develops and sells information technology solutions for marketing. It develops technology to deliver content and targeted advertisements over the internet. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.